-
1 Comment
Aurobindo Pharma Limited is currently in a long term uptrend where the price is trading 6.4% above its 200 day moving average.
From a valuation standpoint, the stock is 56.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.1.
Aurobindo Pharma Limited's total revenue rose by 7.8% to $64B since the same quarter in the previous year.
Its net income has increased by 317.7% to $29B since the same quarter in the previous year.
Finally, its free cash flow fell by 5.6% to $21B since the same quarter in the previous year.
Based on the above factors, Aurobindo Pharma Limited gets an overall score of 4/5.
ISIN | INE406A01037 |
---|---|
Exchange | NSE |
CurrencyCode | INR |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Market Cap | 690B |
---|---|
Beta | 0.54 |
PE Ratio | 19.85 |
Target Price | 1470.8214 |
Dividend Yield | None |
Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for AUROPHARMA.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025